Competing drug | C6 cells (rat glioma) | N417 cells (human small cell lung carcinoma) | ||||||
---|---|---|---|---|---|---|---|---|
IC50 | R | IC50 | R | |||||
18F-FE-SA5845* | ||||||||
(+)-Pentazocine (σ1) | (0.3 nmol/L)/(13 μmol/L) | 0.987 | (4.6 nmol/L)/(10 μmol/L) | 0.996 | ||||
Haldol (σ1, σ2, D2, D3) | (12 nmol/L)/(3.5 μmol/L) | 0.999 | (0.1 μmol/L)/(6.5 μmol/L) | 0.996 | ||||
Raclopride (D2) | 200 μmol/L | 0.991 | 27 μmol/L | 0.995 | ||||
(S)-Ketamine (NMDA) | ND | ND | 52 μmol/L | 0.998 | ||||
11C-SA4503† | ||||||||
(+)-Pentazocine (σ1) | 2.4 μmol/L | 0.957 | 8.6 μmol/L | 0.982 | ||||
Haldol (σ1, σ2, D2, D3) | 0.1 μmol/L | 0.997 | 0.3 μmol/L | 0.994 | ||||
SA4503 (σ1) | 0.2 μmol/L | 0.998 | ND | ND | ||||
(S)-Ketamine (NMDA) | 22 μmol/L | 0.998 | 45 μmol/L | 0.998 |